CN1087681A - 具有抗人体内病原菌感染的被动免疫力的新抗体 - Google Patents

具有抗人体内病原菌感染的被动免疫力的新抗体 Download PDF

Info

Publication number
CN1087681A
CN1087681A CN93119080A CN93119080A CN1087681A CN 1087681 A CN1087681 A CN 1087681A CN 93119080 A CN93119080 A CN 93119080A CN 93119080 A CN93119080 A CN 93119080A CN 1087681 A CN1087681 A CN 1087681A
Authority
CN
China
Prior art keywords
antibody
sequence
light chain
heavy chain
variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93119080A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·格罗斯
M·赫勒
S·霍夫曼
Y·夏朗维特
M·罗森堡
J·C·沙多夫
D·R·施维斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Admiralty Of American Government
US Department of Army
SmithKline Beecham Corp
Original Assignee
Admiralty Of American Government
US Department of Army
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Admiralty Of American Government, US Department of Army, SmithKline Beecham Corp filed Critical Admiralty Of American Government
Publication of CN1087681A publication Critical patent/CN1087681A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN93119080A 1992-09-09 1993-09-09 具有抗人体内病原菌感染的被动免疫力的新抗体 Pending CN1087681A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94165492A 1992-09-09 1992-09-09
US941,654 1992-09-09

Publications (1)

Publication Number Publication Date
CN1087681A true CN1087681A (zh) 1994-06-08

Family

ID=25476840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93119080A Pending CN1087681A (zh) 1992-09-09 1993-09-09 具有抗人体内病原菌感染的被动免疫力的新抗体

Country Status (9)

Country Link
EP (1) EP0659192A4 (ja)
JP (1) JPH08500979A (ja)
KR (1) KR950703573A (ja)
CN (1) CN1087681A (ja)
AU (1) AU4851193A (ja)
CA (1) CA2143417A1 (ja)
NZ (1) NZ256232A (ja)
WO (1) WO1994005690A1 (ja)
ZA (1) ZA936260B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117854601A (zh) * 2024-03-04 2024-04-09 鲁东大学 一种基于基因类型和氨基酸序列的决定性互补区分类方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0782626A1 (en) * 1994-09-19 1997-07-09 Rijkslandbouwuniversiteit Wageningen Gene constructs encoding crop-protecting agents, as well as transformed plants containing and expressing such constructs, and methods of controlling plague organisms and pathogens in crops
SE9500148D0 (sv) * 1995-01-18 1995-01-18 Bioinvent Internatioal Ab Antibodies for use in cancer therapy and diagnosis
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
CN1268394C (zh) * 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2372686T3 (es) * 2001-01-26 2012-01-25 Inhibitex, Inc. Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones.
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
KR102225009B1 (ko) 2007-09-26 2021-03-08 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
NZ588671A (en) 2008-04-11 2012-11-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd VARIANT OF A CONSTANT ANTIBODY REGION
AU2010291835A1 (en) * 2009-09-03 2012-04-19 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR102398736B1 (ko) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
WO2014164553A1 (en) 2013-03-13 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd8
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
FR3025517B1 (fr) * 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2994951A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632909A (en) * 1983-10-31 1986-12-30 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies which block infectivity of malarial parasites to mosquitoes
JPS63267295A (ja) * 1986-12-03 1988-11-04 Sumitomo Chem Co Ltd ヒト抗体、抗体遺伝子及び対応する組換え体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117854601A (zh) * 2024-03-04 2024-04-09 鲁东大学 一种基于基因类型和氨基酸序列的决定性互补区分类方法
CN117854601B (zh) * 2024-03-04 2024-05-14 鲁东大学 一种基于基因类型和氨基酸序列的决定性互补区分类方法

Also Published As

Publication number Publication date
NZ256232A (en) 1997-02-24
KR950703573A (ko) 1995-09-20
EP0659192A1 (en) 1995-06-28
EP0659192A4 (en) 1996-09-11
AU4851193A (en) 1994-03-29
JPH08500979A (ja) 1996-02-06
WO1994005690A1 (en) 1994-03-17
ZA936260B (en) 1994-03-18
CA2143417A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
CN1087681A (zh) 具有抗人体内病原菌感染的被动免疫力的新抗体
CN1202128C (zh) 修饰蛋白的免疫原性
CN1246335C (zh) 用于治疗il－18介导疾病的重组il－18拮抗物
CN1207306C (zh) 用于预防和治疗hiv感染和免疫疾病的肽组合物
CN1211123C (zh) 抗白细胞粘附分子vla－4的人源化抗体
CN1187374C (zh) 人源化的特异于人4－1bb的抗体和含有它的药物组合物
CN1174998C (zh) 用于预防和治疗过敏的肽免疫原
CN1271205C (zh) 重新构建的人抗hm1.24抗体
CN1076966A (zh) 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达
CN1163599C (zh) 抗gpiib/iiia重组抗体
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1077991A (zh) 具有人属性的抗人白细胞介素-5的单克隆抗体的设计，克隆和表达
CN1745100A (zh) 因子ⅷ多肽
CN1273588A (zh) 用于治疗和预防多毒素梭状芽胞杆菌毒素导致的疾病的氨基酸序列
CN1279690A (zh) 可溶性单链t细胞受体蛋白
CN1200737A (zh) 用于人治疗的重组抗cd4抗体
CN1558916A (zh) 产生嵌合异源多聚体的组合物和方法
CN1520423A (zh) 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
CN1688338A (zh) 对免疫系统分子进行人源化的方法
CN1526072A (zh) 埃-巴二氏病毒(ebv)肿瘤相关潜伏膜蛋白的胞外结构域的鉴定方法和与之反应的抗体试剂的选择方法
CN1078250C (zh) 抗免疫球蛋白等模式标本的重整形单克隆抗体
CN1227610A (zh) 抗cd4和趋化因子受体结构域复合物的抗体及其抵抗hiv感染的应用
CN87105411A (zh) B型肝炎病毒表面抗原前s区的t细胞和b细胞抗原决定基
CN1956995A (zh) 抗肥胖免疫原性杂交多肽和包含该杂交多肽的抗肥胖疫苗组合物
CN1531548A (zh) 编码可诱导抗病毒效应的蛋白质的嵌合链

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication